Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States-Reference-Cited by-同舟云学术

Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States

Published:2018-09-06 Issue:10 Volume:29 Page:1425-1435
ISSN:1045-3873
Container-title:Journal of Cardiovascular Electrophysiology
language:en
Short-container-title:J Cardiovasc Electrophysiol

Author:

Patel Nilay¹^ORCID,Viles-Gonzalez Juan²,Agnihotri Kanishk¹,Arora Shilpkumar³,Patel Nileshkumar J.⁴,Aneja Ekta⁵,Shah Mahek⁶,Badheka Apurva O.⁷,Pothineni Naga Venkata⁸^ORCID,Kancharla Krishna⁹,Mulpuru Siva⁹,Noseworthy Peter A.⁹,Kusumoto Fred⁹,Cha Yong Mei⁹^ORCID,Deshmukh Abhishek J.⁹

Affiliation:

1. Internal Medicine Department; Saint Peter s University Hospital; New Brunswick New Jersey

2. Cardiovascular Disease; Tulane University School of Medicine; New Orleans Louisiana

3. Internal Medicine Department; Mount Sinai St Luke's Roosevelt Hospital; New York New York

4. Cardiovascular Department; University of Miami Miller School of Medicine; Miami Florida

5. Internal Medicine Department; Saint Barnabas Medical Center; Bronx New York

6. Cardiovascular Department; Lehigh Valley Healthcare Network; Allentown Pennsylvania

7. Cardiovascular Department; The Everett Clinic; Everett Washington

8. Cardiovascular Department; University of Arkansas for Medical Sciences; Little Rock Arkansas

9. Clinical Cardiac Electrophysiology Program; Mayo Clinic College of Medicine; Rochester Minnesota

Publisher

Wiley

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jce.13701/fullpdf

Reference33 articles.

1. Cardiac resynchronization devices: the Food and Drug Administration's regulatory considerations;Moynahan;J Am Coll Cardiol,2005

2. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial;Young;JAMA,2003

3. The effect of cardiac resynchronization on morbidity and mortality in heart failure;Cleland;N Engl J Med,2005

4. Cardiac resynchronization in chronic heart failure;Abraham;N Engl J Med,2002

5. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure;Bristow;N Engl J Med,2004

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Negative effects of COVID‐19 on the implantation rate of cardiac resynchronization therapy with defibrillator device;Journal of Arrhythmia;2024-01-16

2. Electrocardiographic Predictors of Complete Heart Block During Right Ventricular Lead Implantation in Patients Who Underwent Cardiac Resynchronization Therapy;The American Journal of Cardiology;2023-08

3. Independent and Joint Association of Statin Therapy with Adverse Outcomes in Heart Failure Patients with Atrial Fibrillation Treated with Cardiac Resynchronization Therapy;Journal of Inflammation Research;2022-12

4. Resincronización cardiaca;FMC - Formación Médica Continuada en Atención Primaria;2022-10

5. Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011–2015: Insights from the National Cardiovascular Data Registry;Heart Rhythm O2;2022-08